AllianceBernstein’s Theriva Biologics TOVX Stock Holding History

AllianceBernstein’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1	Closed	-$21K	–	2992
2016 Q2	$21K	Buy	+1	New	+$18.8K	﹤0.01%	2959

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein's TOVX Position: Q3 2016 in Review

AllianceBernstein sold out of Theriva Biologics (TOVX) in Q3 2016, closing a stake of 1 share — an estimated $21K sold.

AllianceBernstein first reported a position in TOVX in Q2 2016 and held it in 1 quarter. The position peaked at $21K in Q2 2016. 60 funds tracked by Wall St. Rank hold TOVX as of Q3 2016.

AllianceBernstein reported no remaining Theriva Biologics position as of Q3 2016 after selling out during the quarter.
AllianceBernstein sold 1 Theriva Biologics share in Q3 2016, an estimated $21K.
AllianceBernstein first reported a position in Theriva Biologics in Q2 2016 and held it in 1 quarter.
AllianceBernstein's Theriva Biologics position peaked at $21K in Q2 2016.
60 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2016.

Based on AllianceBernstein's 13F filing for Q3 2016, filed 10 Nov 2016.